Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma

Jinno, Kenji; Tanimizu, Masahito; Hyodo, Ichinosuke; Nishikawa, Yoshiyuki; Hosokawa, Yasushi; Doi, Toshihiko; Endo, Hisashi; Yamashita, Tetsuji; Okada, Yoshio

doi:10.1007/s005350050099

Cited by 118 publications

(73 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…previous reports by Jinno et al (38) indicated that serum VeGF levels increased gradually along with disease progression in patients with hepatitis, cirrhosis and HCC. there was a significant difference in the level of serum VEGF between HCC and other patient groups, but not among hepatitis patients, cirrhotic patients and normal controls.…”

Section: Serum Levels Of E-cadherin Icam-1 Mmp-2 Vegf Opnmentioning

confidence: 84%

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Zekri

Bahnassy²,

El-Din³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. the global rising incidence of hepatocellular carcinoma (HCC), which parallels the increase of hepatitis C virus (HCV) prevalence, has sparked a renewed interest in discovering additional HCC serum markers. In this study, we investigated the clinical use of serum e-cadherin, ICAM, MMp-2, VeGF, OpN and β-catenin as potential diagnostic makers for HCV/genotype 4-associated HCC. twenty cases of healthy subjects, 11 cases with asymptomatic HCV/genotype 4 carriers (AsC), 28 chronic hepatitis (CH) cases and 32 patients with HCC were enrolled in this study. serum levels of proteins were measured by a sandwich-enzyme-linked (eLIsA) assay. the diagnostic accuracy of each candidate marker was evaluated using receiver-operating characteristic (rOC) curve analysis, reporting the area under the curve (AUC) and its 95% confidence interval (CI). We demonstrated that serum β-catenin levels were significantly elevated in patients with HCC compared to those with CH, AsC and healthy controls. Among the six studied markers, β-catenin was also found to be the only marker that can significantly discriminate between patients with HCC and those with CH; therefore, β-catenin could be considered as a potential marker for early diagnosis of HCV-associated HCC in patients infected with HCV genotype 4. IntroductionHepatocellular carcinoma (HCC) is the fifth most common cancer and one of the leading causes of cancer death in the world (1). It has heterogeneous geographical distribution, with its greatest incidence in Asia and sub-saharan Africa, where hepatitis B infection is endemic (2). Its incidence has also been increasing steadily in the United states and Western europe due to the high prevalence of hepatitis C (3,4). egypt has the highest prevalence of hepatitis C virus (HCV) infection, with 14% of the population infected and seven million with chronic liver hepatitis (5,6). Little is known about the molecular mechanisms by which HCV initiates HCC. Molecular studies directed at mapping the etiology of HCV disease progression to HCC are expected to provide new insights on the management of this increasing problem and hence are of great global health interest. However, the lack of molecular makers that can characterize the stage of HCC, regardless of the etiologic factor, and tumor progression precludes the effective diagnosis and prognosis of HCC. Currently, HCC diagnosis relies on the radiology imaging systems, and elevated serum α-fetoprotein (AFp). serum AFp is not always elevated to a diagnostic level in all patients in small HCC, thus, considerable numbers of patients with more advanced stages would be missed unless other diagnostic tools are used (7,8). Moreover, the level of AFp may be elevated in non-malignant chronic liver diseases, including chronic hepatitis and cirrhosis (9,10). several biomarkers, such as des-γ-carboxyprothrombin/prothrombin induced by vitamin K absence-II, lens cularis agglutininreactive (AFp-L3), and glypican-3, have been examined for their ability to diagnose early HCC (11). However, there is a...

show abstract

Section: Serum Levels Of E-cadherin Icam-1 Mmp-2 Vegf Opnmentioning

confidence: 84%

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Zekri

Bahnassy²,

El-Din³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…The tumor enhancement degree could also truly reflect the distribution characteristics of tumor microvessels within a tumor mass, as the area with the greatest enhancement was often associated with the highest MVD. Higher tumor MVD was shown to be associated with worse degree of [4,10] , thus it is possible to estimate the biological behaviors of HCC in terms of aggressiveness and metastasis by calculating the parameters of HCC T-D curve through dynamic spiral CT scanning.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor angiogenesis plays a fundamental role in the pathogenesis of tumor growth and metastasis [1][2][3] , and significantly influences the biological behaviors of tumor and prognosis of patients [3][4][5][6] . The inhibition or blockade of this angiogenic activity, on the other hand, can slow down the tumor growth rate and positively affect the outcome of patients [7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Single-level dynamic spiral CT of hepatocellular carcinoma: Correlation between imaging features and density of tumor microvessels

Chen¹,

Min²,

Song³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To investigate the correlation of enhancement features of hepatocellular carcinoma (HCC) revealed by single-level dynamic spiral CT scanning (DSCT) with tumor microvessel density (MVD), and to determine the validity of DSCT in assessing in vivo tumor angiogenic activity of HCC. METHODS:Twenty six HCC patients were diagnosed histopathologically. DSCT was performed for all patients according to standard scanning protocol. Time-density curves were generated, relevant curve parameters were measured, and gross enhancement morphology was analyzed. Operation was performed to remove HCC lesions 1 to 2 weeks following CT scan. Histopathological slides were carefully prepared for the standard F 8 RA immunohistochemical staining and tumor microvessel counting. Enhancement imaging features of HCC lesions were correlatively studied with tumor MVD and its intra-tumor distribution characteristics. RESULTS:On DSCT images of HCC lesions, three patterns of time-density curve and three types of gross enhancement morphology were recognized. Histomorphologically, the distribution of positively stained tumor endothelial cells within tumor was categorized into 3 types. Curve parameters such as peak enhancement value and contrast enhancement ratio were significantly correlated with tumor tissue MVD (r=0.508 and r=0.423, P<0.01 and P<0.05 respectively). Both the pattern of time-density curve and the gross enhancement morphology of HCC lesions were also correlated with tumor MVD, and reflected the distributive features of tumor microvessels within HCC lesions. Correlation between the likelihood of intrahepatic metastasis of HCC lesions with densely enhanced pseudocapsules and rich pseudocapsular tumor MVD was found.CONCLUSION: Enhancement imaging features of HCC lesions on DSCT scanning are correlated with tumor MVD, and reflect the intra-tumor distribution characteristics of tumor microvessels. DSCT is valuable in assessing the angiogenic activity and tumor neovascularity of HCC patients in vivo.Chen WX, Min PQ, Song B, Xiao BL, Liu Y, Ge YH. Single-level dynamic spiral CT of hepatocellular carcinoma: Correlation between imaging features and density of tumor microvessels.

show abstract

“…54 Another study reported that plasma VEGF was a promising predictor for distant metastases from HCC. 55 The study reported that the levels were significantly elevated in the HCC group, compared with the control, chronic hepatitis, and cirrhosis groups. Furthermore, stage IV patients with distant metastases demonstrated significantly marked elevation of plasma VEGF compared with the patients at the other stages.…”

Section: Plasma Vegfmentioning

confidence: 96%

Vascular endothelial growth factor in the management of hepatocellular carcinoma

Kaseb

Hanbali

Cotant

et al. 2009

Cancer

110

View full text Add to dashboard Cite

The consumption of antidepressants, especially selective serotonine reuptake inhibitors (SSRI) has been increasing. Because a large fraction of the population is exposed, even a small excess of risk with respect to cancer should be considered. We carried out a record linkage study in Finland utilizing nationwide databases of reimbursed medication and cancer. The study population included all antidepressant drug (AD) users in Finland who had purchased at least 1 prescription between 1998 and 2005, and who had no cancer diagnosis at the date of first purchase. A control population without AD usage (matched by age and sex) was also included. Data consisted of 418,588 pairs of individuals that cumulated 3.3 million person‐years with an average of 4.0 years of follow‐up. 19,365 cancer cases were observed. The most frequent cancers were breast, prostate, lung, colon, and brain cancer. In general, only few associations between the utilization of AD and cancer could be detected. Over four years exposure to AD showed a weak association with increased colon and breast cancer incidence, which could have been caused by bias. As conclusion, no clear evidence of neither beneficial nor harmful association between usage of antidepressant and cancer was found.

show abstract

Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma

Cited by 118 publications

References 20 publications

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma

Single-level dynamic spiral CT of hepatocellular carcinoma: Correlation between imaging features and density of tumor microvessels

Vascular endothelial growth factor in the management of hepatocellular carcinoma

Contact Info

Product

Resources

About